Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10376
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBosanac, Peteren
dc.contributor.authorKurlender, Sen
dc.contributor.authorNorman, Trevor Ren
dc.contributor.authorHallam, Ken
dc.contributor.authorWesnes, Ken
dc.contributor.authorManktelow, Ten
dc.contributor.authorBurrows, Graham Den
dc.date.accessioned2015-05-15T23:48:30Z
dc.date.available2015-05-15T23:48:30Z
dc.date.issued2007-06-01en
dc.identifier.citationHuman Psychopharmacology; 22(4): 223-30en
dc.identifier.govdoc17487935en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10376en
dc.description.abstractAtypical antipsychotics may be beneficial in treating the core psychopathology of anorexia nervosa (AN).An 8 week open-label study of quetiapine was conducted in eight severely ill DSM-IV AN patients consecutively admitted to a specialist eating disorders unit. Participants were assessed by EDE-12, MADRS, YBOCS, SAPS-delusions and CDR neuropsychological battery at baseline, 4 weeks and 8 weeks, and by weekly body mass index (BMI), CGI and extrapyramidal scores. Quetiapine doses ranged from 50 mg to 800 mg per day, according to efficacy and tolerability.Seven participants completed 4 weeks and five participants completed 8 weeks. All participants had clinically significant levels of specific eating disorders psychopathology, and mild to moderately severe depressive symptomatology. Apart from initial mild sedation, no subjects experienced any significant adverse events. Over 4 weeks there was no significant difference in BMI, but a significant difference in the EDE-12 restraint score. There were significant differences on BMI and EDE-12 restraint subscale scores over 8 weeks.A double-blind placebo controlled study is required to further evaluate the therapeutic utility of quetiapine in severely ill AN patients beyond multidisciplinary specialist intervention.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAnorexia Nervosa.drug therapy.psychologyen
dc.subject.otherAntipsychotic Agents.adverse effects.therapeutic useen
dc.subject.otherArousal.drug effectsen
dc.subject.otherBody Mass Indexen
dc.subject.otherDelusions.psychologyen
dc.subject.otherDepression.psychologyen
dc.subject.otherDibenzothiazepines.adverse effects.therapeutic useen
dc.subject.otherDyskinesia, Drug-Induced.epidemiologyen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherNeuropsychological Testsen
dc.subject.otherObsessive Behavior.psychologyen
dc.subject.otherPsychiatric Status Rating Scalesen
dc.subject.otherReaction Time.drug effectsen
dc.subject.otherWeight Gainen
dc.titleAn open-label study of quetiapine in anorexia nervosa.en
dc.typeJournal Articleen
dc.identifier.journaltitleHuman psychopharmacologyen
dc.identifier.affiliationDepartment of Psychiatry, University of Melbourne, and Austin Hospital, Australiaen
dc.identifier.doi10.1002/hup.845en
dc.description.pages223-30en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/17487935en
dc.type.austinJournal Articleen
local.name.researcherNorman, Trevor R
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptPsychiatry (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.